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 ABSTRACT 
Background 
Approximately half of adults in the U.S. fit the criteria for use of anti-obesity 
pharmacotherapy, but only 2% of those receive such treatment. This is in 
sharp contrast to the 8.4% of adults diagnosed with diabetes, with 86% of 
those receiving anti-diabetes pharmacotherapy. In 2012-2014, the first 
medications in 13 years were FDA approved for long-term management of 
obesity.  In 2013-2014, the newest class of anti-diabetes pharmacotherapy, 
subtype 2 sodium-glucose transport protein inhibitors (SGLT2s), were FDA 
approved. 
Methods 
A retrospective analysis of extracted data from the IMS Health National 
Prescription Audit™ and Xponent™ assessed adoption rates of anti-obesity 
pharmacotherapies and SGLT2s using univariate linear regressions.  Volumes 
of new and continuing prescriptions were compared using ratio analyses.  
Prescriber groups were compared by descriptive proportions according to 
prescription volumes, medical specialty, geographic region, and prescriber-
drug overlap. 
Results 
The entire anti-diabetes market was 15 times the entire anti-obesity market. 
The anti-obesity market share was: 74.0% phentermine and 18.6% new anti-
obesity pharmacotherapies. The mean increase in prescriptions per month 
were: 25,259 for SGLT2s (95% CI 23,133-27,383 p<.0001), 5,154 for new 
 anti-obesity pharmacotherapies (95% CI 4,800-5,507 p<.0001), and 2,718 for 
phentermine (95% CI 1,345-4,089 p=0.0003). Medical specialties prescribing 
the majority of the analysis medications were Family Medicine/General 
Practice and Internal Medicine.   Endocrinology had the highest prevalence of 
prescribers of any sub-specialty. 
Conclusions 
The adoption rate of SGLT2s was nearly exponential, while the adoption rate 
of new anti-obesity pharmacotherapies was linear. Considering the relative 
prevalence of obesity to diabetes and that obesity is a major cause of 
diabetes, these results are paradoxical and suggest biases against the 
prescribing of anti-obesity pharmacotherapies. The under-prescribing of anti-
obesity pharmacotherapies is widely acknowledged, but this is the first 
prescription data to demonstrate its extent in the U.S.  
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1 
CHAPTER ONE 
BACKGROUND 
In the United States, more than two thirds (69%) of adults are overweight, more 
than one third have obesity (35%), and 6.4% have extreme obesity.1  Obesity is a 
major risk factor for a constellation of diseases including type 2 diabetes and 
cardiovascular disease. 2  Anti-obesity pharmacotherapy is indicated as an 
adjunct to reduced-calorie diet and increased physical activity in adults with a 
body mass index ≥30 or ≥27 kg/m2 with hypertension, type 2 diabetes, or 
dyslipidemia.  Just under half (46%) of adults in the U.S. fit the criteria for use of 
anti-obesity pharmacotherapy, but only 2% of those receive such treatment.3,4  
This is in sharp contrast to the 8.4% of adults in the U.S. diagnosed with 
diabetes5, with 86% of those receiving anti-diabetes pharmacotherapy6 (Figure1).  
Figure 1. Obesity and diabetes prevalence and pharmacotherapy utilization. 
  
Figure 1. Prevalence of obesity and diabetes in the U.S. adult population and 
pharmacotherapy utilization of anti-obesity pharmacotherapies and anti-diabetes 
pharmacotherapies.   
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It has taken the past 20 years for the world’s leading public health and medical 
bodies to recognize obesity as a disease.  In 1995, the Institute of Medicine 
recognized obesity as a disease and recommended use of pharmacotherapy in 
treatment of the disease.7 In 1997, the World Health Organization followed suit8, 
continuing with the National Institutes of Health in 19989 and in 200010, the 
American College of Physicians in 200511, the American Association of Clinical 
Endocrinologists (AACE) and the American College of Endocrinologists (ACE) in 
201212, and the American Medical Association in 201313.  In June 2013, the 
American Heart Association, the American College of Cardiology, and The 
Obesity Society issued joint guidelines for the management of overweight and 
obesity in adults.14  In February 2015, The Endocrine Society issued clinical 
practice guidelines on the pharmacological management of obesity.15  The 
declaration by each body included the recommendation of using anti-obesity 
pharmacotherapy as an adjunct to behavioral management in appropriate 
individuals. 
The most commonly prescribed anti-obesity pharmacotherapies in the U.S. are: 
phentermine, naltrexone + bupropion, lorcaserin, and topiramate + phentermine. 
Phentermine was FDA-approved in 1959 for short-term treatment of obesity (3 
months). Topiramate + phentermine and lorcaserin were FDA-approved in 2012 
and naltrexone + bupropion in 2014. Topiramate + phentermine, lorcaserin, and 
naltrexone + bupropion (new anti-obesity pharmacotherapies) were the first 
medications in 13 years to receive FDA approval for long-term management of 
obesity in adults.  The newest class of anti-diabetes pharmacotherapy, subtype 2 
3 
sodium-glucose transport protein inhibitors (SGLT2s), served as comparators in 
this analysis due to their similarly timed commercial availability as the new anti-
obesity pharmacotherapies and their mid-range placement in the AACE/ACE 
Glycemic Control Algorithm.16  The SGLT2s include: canagliflozin, dapagliflozin, 
and empagliflozin and were FDA-approved to treat adults with type 2 diabetes 
mellitus in 2013 and 2014.  
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CHAPTER TWO 
MATERIALS AND METHODS 
This study was approved, with the requirement of informed consent waived, by 
the Weill Cornell Medical College Institutional Review Board.  This is a 
retrospective analysis, 2012-2015, of deidentified extracted data from the IMS 
Health National Prescription Audit™ and Xponent™ databases.  IMS Health is 
the industry standard source of national prescription activity for all 
pharmaceutical products in the U.S.  The National Prescription Audit™ is a 
database of all dispensed prescription information from 38,939 pharmacies 
(retail, long-term care, and mail service) across the U.S., which represents 70% 
of the dispensed outpatient prescription volume in the U.S.17  The uncaptured 
prescription volume is projected to 100% by proprietary IMS Health 
methodologies.  Xponent™ contains demographic and dispensed prescription 
information for U.S. prescribers.  Prescriber demographic information is obtained 
by IMS Health from the American Medical Association's Physician Professional 
Data, which are based on clinician self-selected responses. 
Wholesale acquisition costs for each medication were obtained from the Wolters 
Kluwer Clinical Drug Information application, Medi-Span Price Rx™.  Wholesale 
acquisition costs are the manufacturer’s list price for their drug to wholesalers or 
direct purchasers in the U.S. 
Total numbers of active physicians, active physicians per specialty, and active 
physicians per state were obtained from the Association of American Medical 
Colleges’ 2014 Physician Specialty Data Book18 and State Physician Workforce 
Data Book 201319.  Both publications source their data from the same source as 
5 
IMS Health, the American Medical Association’s Physician Masterfile, which is 
informed by the American Medical Association's Census of Physicians and 
National Graduate Medical Education Census.   
For this analysis, medical specialties in Xponent™ were grouped according to 
the groupings defined in the Association of American Medical Colleges’ 
publications (e.g. Endocrinology, Diabetes & Metabolism and Diabetes were 
group together as Endocrinology).  Prescriber specialties were further grouped 
into physicians and non-physicians (e.g. nurse practitioner, physician assistant, 
chiropractor, dentist, podiatrist).  The continental states were grouped into 
regions according to the U.S. Census Bureau.  Alaska and Hawaii were grouped 
into the Pacific Region.   
This analysis assessed the adoption rate of anti-obesity pharmacotherapies and 
SGLT2s by evaluating the change in mean prescriptions per month over the 
analysis period using univariate linear regressions.  National volumes of 
dispensed prescriptions were described according to frequency over time.  
Volumes of new and continuing prescriptions were compared using ratio 
analyses.  Prescriber groups were compared by descriptive proportions 
according to prescription volumes, medical specialty, geographic region, and 
prescriber-drug overlap. 
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CHAPTER THREE 
RESULTS 
As of August 2015, the entire anti-diabetes pharmacotherapy market, excluding 
insulin, was 15 times the entire anti-obesity pharmacotherapy market. SGLT2s 
comprised 4.9% of the anti-diabetes pharmacotherapy market, which was 
equivalent to three-quarters of the entire anti-obesity pharmacotherapy market 
(Figure 2).  
Figure 2. Dispensed volumes of anti-obesity and anti-diabetes 
pharmacotherapies and SGLT2s. 
 
Figure 2. Volume of prescriptions of all anti-obesity pharmacotherapies, all anti-
diabetes pharmacotherapies (excluding insulin), and SGLT2s dispensed in the 
U.S., 2012-2015. 
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prescriptions per month were: 25,259 for SGLT2s (95% CI 23,133-27,383 
p<.0001), 5,154 for new anti-obesity pharmacotherapies (95% CI 4,800-5,507 
p<.0001), and 2,718 for phentermine (95% CI 1,345-4,089 p=0.0003) (Figure 3, 
Table 1). For each new prescription dispensed there were 5.4 continuing 
prescriptions dispensed for phentermine, 4.6 for SGLT2s, and 1.4 for new anti-
obesity pharmacotherapies.   
Figure 3. Dispensed volumes of phentermine, new anti-obesity 
pharmacotherapies, and SGLT2s. 
 
Figure 3. Volume of prescriptions of phentermine, new anti-obesity 
pharmacotherapies, and SGLT2s dispensed in the U.S, 2012-2015. 
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Table 1. Output from separate univariate linear regressions by drug category to 
estimate mean change in prescriptions per month, as presented in Figure 3. 
   Estimate 
Std. 
Error 95% CI 
t 
value Pr(>|t|)
SGLT2s Intercept -109,595.00 17,788.00 (-146,093.58, -73,097.20) -6.16  
Month 25,259.00 1,036.00 (23,133.65, 27,383.66) 24.39 <.0001 
New Anti-
Obesity 
Intercept -18,225.60 3,689.90 (-25,724.34, -10,726.84) -4.94  
Month 5,153.90 173.90 (4,800.51, 5,507.37) 29.64 <.0001 
Phentermine Intercept 568,472.80 14,325.70 (539,359.45, 597,586.08) 39.68  
Month 2,717.60 675.20 (1,345.47, 4,089.79) 4.03 0.0003 
 
 
Of the 900,000 prescribers in the IMS Health Xponent™ database, from 2012 to 
2015, 173,882 (19%) prescribed phentermine, 104,612 (12%) prescribed a new 
anti-obesity pharmacotherapy, and 102,002 (11%) prescribed an SGLT2.  Of the 
829,962 active physicians in the U.S., 129,414 (16%) prescribed phentermine, 
79,624 (10%) prescribed a new anti-obesity pharmacotherapy, and 70,898 (9%) 
prescribed an SGLT2 (Table 2).  The top eight most frequent prescribing medical 
specialties of each drug group represent: 62% of prescribers and 75% of 
prescriptions of phentermine, 69% of prescribers and 81% of prescriptions of 
new anti-obesity pharmacotherapies, and 66% of prescribers and 80% of 
prescriptions of SGLT2s (Table 2).   
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Table 2. Prescriber groups compared by descriptive proportions according to 
prescription volumes, medical specialty, geographic region, and prescriber-drug 
overlap.  Prescriber-Drug Overlap represents the percentage of prescribers of 
the column drug category who also prescribed the row drug category. 
 
2012-2015 Phentermine 
New Anti-Obesity 
Pharmacotherapies SGLT2s 
Group A B C A B C A B C 
Prescribers in Xponent™ 19 100 100 12 100 100 11 100 100 
Active Physicians in U.S. 16 74 81 10 76 86 9 70 83 
Primary Specialty           
Family Medicine/General Practice 48 30 42 32 34 34 32 34 33 
Internal Medicine 27 18 19 21 22 27 22 24 25 
Endocrinology 37 1 2 47 3 13 64 4 22 
Obstetrics/Gynecology 25 6 7 12 5 4    
Psychiatry 10 2 1 4 2 1    
Emergency Medicine 8 2 1 2 1 <1 2 1 <1 
General Surgery 11 2 2 4 1 1    
Cardiovascular Diseases    7 1 1 5 1 <1 
Internal Medicine/Pediatrics        14 1 <1 
Geriatric Medicine        13 1 <1 
Pediatrics 4 1 1        
Nephrology        4 <1 <1 
Unavailable  2 <1  2 <1  10 3 
Physicians by Region           
South 20 43 46 13 44 46 11 42 41 
Midwest 16 22 16 10 21 16 9 22 16 
West 14 20 10 8 17 11 6 16 13 
Northeast 10 14 7 7 17 12 7 19 12 
Pacific 12 1 <1 7 <1 <1 8 1 <1 
Unavailable  <1 <1  <1 <1  <1 <1 
Prescriber-Drug Overlap           
Phentermine   69 57 
New Anti-Obesity 
Pharmacotherapies 41   51 
SGLT2s 33 50   
Legend          
A: % of group who prescribed drug(s)= drug prescribers from group / active physicians in group  
B: % of drug prescribers from group= drug prescribers from group / all prescribers of drug(s)  
C: % of drug Rxs in U.S. from group= drug prescriptions from group / all prescriptions of drug(s)  
Specialties reported represent the top 8 most frequent prescribing specialties per drug category.  
 
The Medicine sub-specialty with the highest prevalence of prescribers of all drug 
categories is Endocrinology (n=6,519), with 37% (n=2,388) having prescribed 
phentermine, 47% (n=3,040) having prescribed a new anti-obesity 
pharmacotherapy, and 64% (n=4,180) having prescribed an SGLT2 (Table 2, 
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Figure 4).   Further, endocrinologists prescribed the new anti-obesity 
pharmacotherapies and SGLT2s at a higher rate than any other specialty.  In 
Table 2, the differential between columns B and C indicate if specialties are 
prescribing at rates relative to their proportions or if they are exceeding it.  The 
significant differentials of this type are: Family Medicine/General Practice with 
phentermine (by 12%), Internal Medicine with new anti-obesity 
pharmacotherapies (by 5%), and Endocrinology with new anti-obesity 
pharmacotherapies (by 10%) and with SGLT2s (by 18%).   
Figure 4. Prevalence of physicians, by medical specialty, prescribing 
phentermine, new anti-obesity pharmacotherapies, and SGLT2s.  
 
Figure 4. Prevalence of physicians, by medical specialty, prescribing 
phentermine, new anti-obesity pharmacotherapies, and SGLT2s in the U.S, 
2012-2015. 
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Medical specialties prescribing the majority of each of the anti-obesity 
pharmacotherapies and the SGLT2s were Family Medicine/General Practice and 
Internal Medicine (Table 2, Figures 5, 6, 7).  The top medical specialties common 
to all three drug categories are: Family Medicine/General Practice, Internal 
Medicine, Endocrinology, and Emergency Medicine.  The top medical specialties 
common to the anti-obesity drug categories, but not SGLT2s are: 
Obstetrics/Gynecology, Psychiatry, and General Surgery.  The top medical 
specialties prescribing SGTL2s, but neither anti-obesity drug category are: 
Internal Medicine/Pediatrics, Geriatric Medicine, and Nephrology.  The 
Cardiovascular Diseases specialty is common among the top medical specialties 
prescribing new anti-obesity pharmacotherapies and SGLT2s, but not 
phentermine.  Pediatrics is among the top medical specialties prescribing 
phentermine, but neither of the other drug categories. 
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Figure 5.  Percent of phentermine prescribers and prescriptions by specialty.   
 
Figure 5. Percent of phentermine prescribers and prescriptions by specialty in the 
U.S, 2012-2015. 
 
Figure 6. Percent of new anti-obesity pharmacotherapy prescribers and 
prescriptions by specialty. 
 
Figure 6. Percent of new anti-obesity pharmacotherapy prescribers and 
prescriptions by specialty in the U.S, 2012-2015. 
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Figure 7. Percent of SGLT2 prescribers and prescriptions by specialty. 
 
Figure 7. Percent of SGLT2 prescribers and prescriptions by specialty in the U.S, 
2012-2015. 
 
 
The geographic region with the highest: prevalence of physician prescribers 
(Table 2, Figure 8), percent of physician prescribers, and percent of dispensed 
prescriptions in each drug category is the South, followed by the Midwest (Table 
2, Figures 9, 10, 11).   
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Figure 8.  Prevalence of physicians, by region, prescribing phentermine, new 
anti-obesity pharmacotherapies, and SGLT2s. 
 
Figure 8. Prevalence of physicians, by region, prescribing phentermine, new anti-
obesity pharmacotherapies, and SGLT2s in the U.S, 2012-2015. 
 
Figure 9. Percent of phentermine prescribers and prescriptions by region. 
 
Figure 9. Percent of phentermine prescribers and prescriptions by region in the 
U.S, 2012-2015. 
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Figure 10. Percent of new anti-obesity pharmacotherapy prescribers and 
prescriptions by region. 
 
Figure 10. Percent of new anti-obesity pharmacotherapy prescribers and 
prescriptions by region in the U.S, 2012-2015. 
 
Figure 11. Percent of SGLT2 prescribers and prescriptions by region. 
 
Figure 11. Percent of SGLT2 prescribers and prescriptions by region in the U.S, 
2012-2015. 
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The highest percentage of overlap-prescribing are of new anti-obesity 
pharmacotherapy prescribers: 69% have also prescribed phentermine, while 
41% of phentermine prescribers have also prescribed a new anti-obesity 
pharmacotherapy.  Of SGTL2 prescribers, 57% have also prescribed 
phentermine, while the inverse represents the lowest percentage overlap: 33% of 
phentermine prescribers have prescribed an SGLT2.   Fifty percent of prescribers 
of a new anti-obesity pharmacotherapy have prescribed an SGLT2, while 51% of 
prescribers of an SGLT2 have prescribed a new anti-obesity pharmacotherapy 
(Table 2).    
The wholesale acquisition costs of a 30-day supply of the new anti-obesity 
pharmacotherapies are $199.50, with the exception of the two lower dose 
strengths of topiramate + phentermine, which are $170.65 and $165.20.  The 
average wholesale acquisition cost of generic phentermine is $37.14.  The 
wholesale acquisition costs of the SGLT2s range from $342.82 to $342.94.   
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CHAPTER FOUR 
DISCUSSION 
The adoption rate of SGLT2s was nearly exponential, while the adoption rate of 
new anti-obesity pharmacotherapies was linear. Echoing the findings of Xia Y, et 
al., the geographic distribution of dispensed anti-obesity pharmacotherapies4 and 
SGLT2s match the geographic prevalence of obesity20 and diabetes21.  The 
specialties that are expected to treat obesity and diabetes (Family 
Medicine/General Practice, Internal Medicine, and Endocrinology) are the top 
prescribing medical specialties.  That endocrinologists prescribe the new anti-
obesity pharmacotherapies and SGLT2s in the highest proportion of any 
Medicine sub-specialty reflects that they are operating within their area of 
expertise. Endocrinologists; however, only comprise 0.8% of active physicians in 
the U.S., which is not sufficient to significantly impact the obesity epidemic.   
The similar proportions and types of prescribers across the drug categories 
indicate that there is an awareness among prescribers of anti-obesity 
pharmacotherapies and a comfort with using them.  The disparity in prescription 
volumes and in the ratio of new prescriptions to continuing prescriptions between 
anti-obesity and anti-diabetes pharmacotherapies indicate that there are barriers 
to anti-obesity pharmacotherapy initiation and perseverance.  This is likely the 
result of multiple factors stemming from the retarded recognition of obesity as a 
disease by leading public health and medical bodies.  An analysis of the National 
Ambulatory Medical Care Survey and the Behavioral Risk Factor Surveillance 
System indicated that less than half of adults with obesity are being advised to 
lose weight by healthcare professionals.22  Cited barriers include physician, 
18 
patient, and medical system factors: lack of reimbursement, limited time during 
office visits, lack of training in counseling, competing demands, low confidence in 
the ability to treat and change patient behaviors, limited resources, the 
perception that patients are not motivated, and a paucity of proven and effective 
interventions to treat obesity.22   
Prescribers and patients likely have a reduced sense of urgency to treat obesity 
compared to diseases such as diabetes.  They may also have a higher threshold 
for initiating anti-obesity pharmacotherapy than the guidelines recommend.   
Barriers to perseverance may include a lower threshold to capitulation, i.e. not 
taking into consideration the chronic progressive nature of obesity, as compared 
to the clinical approach with diseases such as diabetes and hypertension where, 
it is standard practice for patients to continue on long-term polypharmacy 
regimens despite many remaining at sub-optimal targets.  The disparate study 
drug discontinuation rates in clinical trials of anti-obesity pharmacotherapies 
(33% for phentermine23, 38% for topiramate + phentermine24, 44% for 
lorcaserin25, 46% for naltrexone + bupropion26) and SGLT2s (12% for 
canagliflozin27, 14% for dapagliflozin28, 9% for empagliflozin29) demonstrate this 
phenomenon.  The most common reasons for discontinuation were: non-
compliance, lost to follow up, lack of efficacy, and adverse events.   
Effectiveness expectations for anti-obesity pharmacotherapy by patients and 
physicians may be at the cosmetic level and not at the clinically meaningful level, 
which is considered ≥5% weight loss.13  For a drug to receive FDA-approval for 
the management of obesity, it must meet at least one of the following efficacy 
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criteria: 1) ≥5% difference in mean 1-year weight loss between active-treated and 
placebo groups or 2) ≥35% subjects in the active-treated group lose ≥5% of body 
weight after 1 year.  In clinical trials, mean bodyweight change observed in those 
completing the trials hover just above the clinically meaningful threshold: -7% 
after 6 months with phentermine23; -10% on the low dose and -12% on the high 
dose after 1 year with topiramate + phentermine24; -8% after 1 year with 
lorcaserin25; and -8% after 1 year with naltrexone + bupropion26.  Comparatively, 
the mean 6-month glycated hemoglobin (HbA1c) reductions and bodyweight 
changes observed in the SGLT2 clinical trials were: -1.16% Hba1c and -3.3% 
bodyweight with canagliflozin27, -0.89% HbA1c and -4.3% bodyweight with 
dapagliflozin28, -0.78% HbA1c and -2.48% bodyweight with empagliflozin29.  
Achieving 5-10% weight loss is associated with an increased likelihood of 
achieving a -0.5% reduction in HbA1c in overweight adults with type 2 diabetes 
(odds ratio 3.52).30  The efficacy on glycemic control in overweight adults with 
type 2 diabetes has been studied as a secondary endpoint in clinical trials of two 
of the anti-obesity pharmacotherapies.  In those who completed the trials, HbA1c 
reductions and bodyweight changes observed were: -1.1% HbA1c and -5.8% 
bodyweight after 1 year with lorcaserin31 and -0.4% HbA1c and -9.0% 
bodyweight after 2 years with topiramate + phentermine32. 
The notion of physicians avoiding all available medications for treatment of a 
disease because of a perceived lack of effectiveness is seemingly unique to this 
field.  In other disease areas, such as dyslipidemia or psychiatry, first and second 
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generation medications were extensively prescribed until improved third and 
fourth generation medications became available.    
In a cohort study of adults with obesity, patients were presented with weight loss 
interventions and thoroughly explained the risks, benefits, and efficacy evidence 
of each.  A choice of one intervention was available to each patient at a cost of 
$5 or $10 per month.  Based on the information presented, the patients chose an 
intervention in the following proportions: topiramate + phentermine 31%, meal 
replacements 27%, recreation center membership 22%, clinic-based weight loss 
program 10%, Weight Watchers 6%, none 3%, phentermine 1%.  The highest 
percentage of subjects chose topiramate + phentermine, which was the 
intervention that was presented with the highest efficacy.  These results indicate 
that when the time is taken to explain the evidence base of all available 
treatments and when the costs are relatively leveled, patients will chose a 
pharmacotherapy option.33   
An analysis of the National Health and Nutrition Examination Survey (NHANES) 
reported that the weight loss strategy most associated with a self-reported 
bodyweight loss of ≥10% in the prior year, among adults with obesity, was anti-
obesity pharmacotherapy (odds ratio 2.05).  Yet, the analysis also indicated that 
anti-obesity pharmacotherapy was reported as the least utilized weight loss 
strategy (3.5%) among adults with obesity who had attempted to lose weight in 
the prior year.34 
To bridge the gap between obesity clinical guidelines and current physician 
practice, the American Board of Obesity Medicine was established in 2011 with 
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board certification and maintenance examinations.  Consequently, obesity 
medicine clinical fellowships, preparatory to the certification examination, are 
being established at academic medical centers throughout the U.S.  As of 2015, 
1,182 physicians have been certified as Diplomates of the American Board of 
Obesity Medicine, making it the fastest growing Medicine sub-specialty in the 
U.S.35  The majority of Diplomates are from the following medical specialties: 
Surgery, Pediatrics, Obstetrics-Gynecology, Internal Medicine, Family Medicine, 
and Endocrinology.35  The number of certificates issued in 2014 was equivalent 
to those issued the same year for Infectious Disease, and more than those 
issued, for Endocrinology, Rheumatology, or Geriatric Medicine, as examples.36 
Cost is another barrier to anti-obesity pharmacotherapy initiation and 
perseverance.  While new anti-obesity pharmacotherapy wholesale acquisition 
costs are somewhat lower than that of SGLT2s, the lack of insurance coverage 
makes anti-obesity pharmacotherapy far less affordable for most Americans. 
Anti-obesity pharmacotherapies are either excluded from insurance formularies, 
thus limiting to those with the means of self-pay, or require prior authorization4, 
thus requiring significantly more physician and office staff time to prescribe.  This 
is in contrast to SGLT2s, which are included in insurance formularies and, 
depending on the plan, are categorized as low as Tier 1, i.e. having the lowest 
copay available. As of 2013, only 14 state Medicaid programs provided coverage 
for at least one anti-obesity pharmacotherapy and all required prior authorization.  
Anti-obesity pharmacotherapy is not included in the Medicare Part D formulary4.   
From survey results of 9,000 adults in the U.S., 84% reported not having 
22 
insurance coverage for anti-obesity pharmacotherapy, which was even reported 
when their employers offered employee wellness programs that targeted BMI.37 
The fact that phentermine, which was FDA-approved in 1959 for short-term use 
and with little clinical trial data, remains the most frequently prescribed anti-
obesity pharmacotherapy, by a large margin, is likely due to its low cost and its 
familiarity among patients and prescribers.  Phentermine’s high proportion of 
continuing prescriptions to new prescriptions indicates that it is often being 
prescribed off-label, i.e. for longer than 3 months.15  Ironically, the very low 
continuing prescription to new prescription ratio of new anti-obesity 
pharmacotherapies, which are approved for long-term use, indicate that they are 
being used for the short-term.  The cyclical nadirs in the volume of dispensed 
phentermine prescriptions occurring each December, followed immediately by a 
dramatic uptick, are likely explained by the New Year’s Resolution phenomenon, 
indicating that phentermine prescribing, and ostensibly all anti-obesity 
pharmacotherapy prescribing, is patient driven.    
This analysis captures the early-phase adoption and prescribing patterns of the 
first medications in 13 years to receive FDA approval for long-term management 
of obesity.  Considering the relative prevalence of obesity to diabetes and that 
obesity is a major cause of diabetes, these results are paradoxical, suggest 
biases against the prescribing of anti-obesity pharmacotherapies, and highlight 
an unmet need.  The under-prescribing of anti-obesity pharmacotherapies is 
widely acknowledged, but this is the first prescription data to demonstrate its 
extent in the U.S.  
23 
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